• Return to Headlines

Uptrend Call Working As Progenics Pharm Stock Rises 14.7% (PGNX)

By David Diaz

SmarTrend identified an Uptrend for Progenics Pharm (NASDAQ:PGNX) on February 26th, 2018 at $6.32. In approximately 2 months, Progenics Pharm has returned 14.72% as of today's recent price of $7.25.

In the past 52 weeks, Progenics Pharm share prices have been bracketed by a low of $4.00 and a high of $11.72 and are now at $7.25, 81% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.1% while the 200-day MA has slid 1%.

Progenics Pharmaceuticals, Inc. is a biopharmaceutical company. The Company develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Progenics' principal programs are directed toward supportive care, virology (human immunodeficiency virus and hepatitis C virus infections), and oncology.

SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any shifts in the trajectory of Progenics Pharm shares.

Log in and add Progenics Pharm (PGNX) to your watchlist today so you can receive a real-time alert when the shares are about to change trend.

Keywords: spotlights progenics pharm

Ticker(s): PGNX